Key Takeaways; Cannabis Sector Organigram to Acquire Aurora Cannabis in C$561 Million Deal, Creating Global Cannabis Powerhouse Canopy Growth Posted 22% Revenue Growth as International Cannabis Sales Surged 141% Key Takeaways; Psychedelic Sector Bright Minds Biosciences Received Partial FDA Clinical Hold on BMB-101 Phase 2 Epilepsy Trial Optimi Health Established Australian Subsidiary to Expand Psychedelic […]
Bright Minds Biosciences’ further studies or protocol changes could become a path past the FDA’s recent hold decision. Read more on DRUG stock here.
NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a clinical stage biotechnology company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that it will participate in the Foundation for Prader-Willi Research (FPWR) 2026 Research Symposium, October 7-8, and the P
Detailed price information for Bright Minds Biosciences Inc (DRUG-Q) from The Globe and Mail including charting and trades.
NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences: EVENT:Cantor Global Healthcare Conference 2026 DATE:Wednesday, September 9,
Does Bright Minds Biosciences Inc. (DRUG) have what it takes to be a top stock pick for momentum investors? Let's find out.
The average of price targets set by Wall Street analysts indicates a potential upside of 97% in Bright Minds Biosciences Inc. (DRUG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
This is the newest page. Registered accounts read further back.